The current study not only provides novel insights into the molecular mechanisms underlying the pancreatic cancer pathogenesis but also paves the way for the development of more effective therapeutic strategies for pancreatic cancer, targeting m6A regulators. This evidence concerns the gene METTL3 and pancreatic neoplasm.